Lifeline Biotechnologies earlier this month announced that the company has recently provided patient cases to Nanyang Technical University to aid in the development of the First Warning System s (FWS) interpretive analytical system.

One objective is to make it more user friendly for women to assist in the detection of breast cancer.

Originally, the FWS was worn by women for 48 hours, with eight sensors on each breast. This length of time caused issues because the longer the testing period, the more the likelihood women would accidentally loosen a sensor and send faulty data. After analyzing the patient cases, Lifeline, along with the work at Nanyang Technical University, has been working to reduce the testing period to 24 hours or less, which will make it more user friendly for women and increase the accuracy of the FWS.

We believe that shortening the time that women have to wear the device will provide more comfort and not interrupt their daily activities. Our enhancements to the software will enable us to cut down the testing time in half, possibly less, and make the detection of breast cancer an easier process, said Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies is in the process of securing FDA clearance, via a 510(k) for its First Warning System, and will continue to update its shareholders regarding its progress on a regular basis.

Lifeline Biotechnologies is a medical technology company that is focused on completing the development of the First Warning System, which was designed to assist in the early detection of breast cancer.

((Comments on this story may be sent to newsdesk@closeupmedia.com))